Currently in shortage
Device component shortage affecting SoloStar pen manufacture. Vials form unaffected. Critical medicine — patients must not stop insulin.
Expected resolution: 30 June 2025
Alternatives:
- Lantus vials — same product, different device (draw with syringe)
- Tresiba (insulin degludec) — alternative long-acting insulin
- Levemir (insulin detemir)
insulin glargine
Lantus
100 units/mL · injection · Insulin
PBS Pricing
| General patient co-payment | $31.60 |
| Concession co-payment | $7.70 |
| Full dispensed price | $42.80 |
PBS Information
- Item code
- 1011J
- Drug name
- insulin glargine
- Brand name
- Lantus
- Manufacturer
- Sanofi
- Formulation
- injection
- Strength
- 100 units/mL
- Max quantity
- 10 units
- Max repeats
- 5
- PBS listed
- Yes
- Therapeutic group
- Insulin
TGA Reference: TGA-MSI-2025-017 · Sponsor: Sanofi-Aventis Australia Pty Ltd
MedWatch is for informational purposes only and does not constitute medical advice. Never stop or change your medicines without consulting your doctor or pharmacist. In an emergency, call 000. Medication queries: National Medicines Line 1300 633 424.